Our blog

We tested a drug to treat agitation in Alzheimer’s patients

3 de June de 2021

The General University Hospital of Catalonia is the first recognized center in Europe to evaluate…

Compartir:
Posted in: Alzeimer, Uncategorised

The General University Hospital of Catalonia (HUGC), through the Clinical Research Unit (UDIC), has included the world’s first patient in a phase I clinical trial on Alzheimer’s.

3 de June de 2021

This study could improve the efficacy and safety of the products being evaluated to try…

Compartir:
Posted in: Alzeimer, Uncategorised

FDA approves sublingual apomorphine in off periods

22 de July de 2020

The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…

Compartir:
Posted in: Parkinson, Uncategorised

US authorizes an intranasal levodopa.

8 de April de 2020

An intranasal levodopa has been authorized in the US to treat off blockages, called Inbrija….

Compartir:
Posted in: Parkinson

Levodopa infusion pump

2 de April de 2020

Levodopa infusion pump We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations….

Compartir:
Posted in: Parkinson

Activation of phase I trial in Progressive Supranuclear Palsy

11 de March de 2020

Our Unit has achieved to be activated in this outstanding project  and so serious pathology….

Compartir:
Posted in: Parkinson

We continue a phase I clinical trial in Parkinson

5 de March de 2020

We appreciate the great effort made by our patients to contribute to the development of…

Compartir:
Posted in: Parkinson

An amazing Phase I trial in Parkinson

9 de January de 2020

We have been activated in this trial that evaluates the safety of an innovative compound…

Compartir:
Posted in: Parkinson

Our clinical trials unit remains in prominent position

9 de January de 2020

We have reached the first position, in December 2019, in the international inclusion of patients…

Compartir:
Posted in: Alzeimer, News, Parkinson

Positive result of the GRIFOLS trial in Alzheimer’s

12 de December de 2019

Grifols has reported to the press the positive result of the AMBAR trial in patients…

Compartir:

Tavapadon (Cerevel): A very different dopamine agonist

29 de November de 2019

The UDIC has been selected to initiate a line of several clinical trials with this…

Compartir:
Posted in: Parkinson

An innovative and surprising therapy in Parkinson’s disease

29 de November de 2019

Our team will begin the evaluation of a novel drug that is administered intrathecally. It…

Compartir:
Posted in: Parkinson
Page 1 of 31 2 3

1 Nuevo anticuerpo monoclonal antialfasinucleina Ensayo Clínico de fase II para evaluar eficacia y seguridad
en enfermedad de Parkinson inicial en pacientes que no reciben medicamentos antiparkinsonianos en el momento actual. 2 Nuevo fármaco antipsicótico en cualquier tipo de demencia. Ensayo de Fase III que evalúa un antipsicótico
en cualquier tipo de delirio o alucinaciones. Sin acción antidopaminérgica, especialmente indicado en Parkinson
o en situaciones de mala respuesta a los neurolepticos
Compartir: